ADAPY (Adaptimmune Therapeutics) Other Long-Term Liabilities: $4.49 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Other Long-Term Liabilities?

Adaptimmune Therapeutics ADAPY +5.80% Other Long-Term Liabilities is $4.49 Mil as of Jun. 2025.

Adaptimmune Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2025 was $4.49 Mil.

Adaptimmune Therapeutics's quarterly other long-term liabilities increased from Dec. 2024 ($4.27 Mil) to Mar. 2025 ($4.37 Mil) and increased from Mar. 2025 ($4.37 Mil) to Jun. 2025 ($4.49 Mil).

Adaptimmune Therapeutics's annual other long-term liabilities increased from Dec. 2022 ($1.30 Mil) to Dec. 2023 ($1.40 Mil) and increased from Dec. 2023 ($1.40 Mil) to Dec. 2024 ($4.27 Mil).

Adaptimmune Therapeutics Other Long-Term Liabilities Related Terms

Adaptimmune Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Other Long-Term Liabilities Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.67 1.30 1.40 4.27

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 4.94 4.27 4.37 4.49

Adaptimmune Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $4.49 Mil mean?
Adaptimmune Therapeutics (ADAPY) has a Other Long-Term Liabilities of $4.49 Mil as of Jun. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Other Long-Term Liabilities too high?
Adaptimmune Therapeutics' current Other Long-Term Liabilities is $4.49 Mil.
How does Adaptimmune Therapeutics' Other Long-Term Liabilities compare to BCLI and APRE?
Adaptimmune Therapeutics' Other Long-Term Liabilities of $4.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Other Long-Term Liabilities is $4.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Other Long-Term Liabilities of $4.49 Mil. The current Other Long-Term Liabilities is $4.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Other Long-Term Liabilities is $4.49 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].